MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression …

Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20,
was the first monoclonal antibody to be approved for therapeutic use. Treatment with …

The anti-CD38 monoclonal antibody daratumumab is well tolerated and has high single
agent activity in heavily pretreated relapsed and refractory multiple myeloma (MM) …

Given that the FcγRIIIa receptor 158V allotype displays a higher affinity for human
immunoglobulin G1 and increased antibody-dependent cellular cytotoxicity, the aim of this …

Purpose: Although rituximab is now routinely used in the treatment of B-cell non-Hodgkin's
lymphoma, the mechanism of its antitumor effect is not clear. One potential mechanism of …

Purpose The anti–HER-2/neu monoclonal antibody trastuzumab has been shown to engage
both activatory (fragment C receptor [FcγR] IIIa; FcγRIIa) and inhibitory (FcγRIIb) antibody …

Despite the clinical success of anti-CD20 monoclonal antibody (mAb) in the treatment of
lymphoma, there remains considerable uncertainty about its mechanism of action. Here we …

Purpose Fludarabine and cyclophosphamide (FC), which are active in treatment of chronic
lymphocytic leukemia (CLL), are synergistic with the monoclonal antibody rituximab in vitro …

Therapeutic monoclonal antibodies (mAbs) that target the CD20 antigen on B cells are
successfully used in the clinic for the depletion of B cells to treat various forms of cancer and …

Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …